© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#follicular lymphoma

immune cells attack cancer cells
FDA Approves Yescarta for Follicular Lymphoma
scientist looks through microscope
New Lymphoma Drug Shows Promise in Clinical Trials
What You Should Know About Lymphoma
Eileen Walther celebrates life despite her numerous challenges with cancer

Living With Intention With Mucosal Melanoma: Eileen Walther’s Story

Surgery for this rare cancer required the removal of Walther’s left eye. “This is my journey,” she said, “and I have to travel it.”
An illustration of a monoclonal antibody drug attacking cancer cells. An illustration of a monoclonal antibody drug attacking cancer cells

FDA Approves Columvi for Large B-Cell Lymphomas

More than 40% of patients treated with the bispecific T-cell engager experienced complete remission.

Now Approved Cancer Drugs — Spring 2023

Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.

FDA Approves Lunsumio for Treatment of Follicular Lymphoma

Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.

New COVID Vaccine May Better Protect Cancer Patients

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
T cells attack a cancer cell

FDA Approves New CAR-T Therapy for Large B-Cell Lymphoma

Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.

FDA Approves Ukoniq for Marginal Zone and Follicular Lymphoma

Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.

Rituxan

Tazverik

FDA Approves Tazverik for Follicular Lymphoma

A study showed a 69% response rate for patients whose cancer carries the targeted mutation.

FDA Approves Revlimid for Follicular and Marginal Zone Lymphoma

Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.

Gazyva

Aliqopa

A patient’s T cells arrive at the Novartis manufacturing facility in Morris Plains, where they will be re-engineered to recognize and fight cancer and healthy cells expressing a specific antigen in the patient’s body.

FDA Approves Kymriah for Adults with Relapsed or Refractory Large B-Cell Lymphoma

The overall response rate was 50%, with a complete response rate of 32%.

FDA Approves Kymriah CAR-T Therapy for Lymphoma

The custom immunotherapy is now indicated for adults with relapsed or refractory lymphoma.
A patient’s T cells arrive at the Novartis manufacturing facility in Morris Plains, where they will be re-engineered to recognize and fight cancer and healthy cells expressing a specific antigen in the patient’s body.

Kymriah CAR-T Therapy Leads to Long-Term Remission in Adults With Lymphoma

Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.
Advertisement
Science News
Blog: Damon Runyon Cancer Research Foundation

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.